Citations

Showing 10 of 108094 citations.

Seronegative Mediastinal Coccidioidomycosis as a Novel Presentation of CTPS1 Combined Immunodeficiency
Krase, Ifat Z , Woodward, James , Bauer, Cindy S. , Miller, Holly, Sacco, Keith , Sacco, Keith A , Woodward, James

Mayo Clinic

Open Forum Infectious Diseases | August 13, 2022 | Volume: 9 | Issue: 8 | Pages: No page available

10.1093/ofid/ofac403 | PMID 35983265 Get It

Abstract Inborn errors of immunity may present with susceptibility to coccidioidomycosis. This is especially so in disorders impairing the interferon-γ and interleukin 12 signaling axis. We describe the first case of cytidine nucleotide triphosphate synthetase 1 (CTPS1) deficiency, a combined immunodeficiency impairing lymphocyte proliferation, presenting with coccidioidomycosis.
Evaluating the Link Between Self-Reported Endometriosis and Female Sexual Dysfunction
Ghaith, Summer , Smith, Taryn , Kapoor, Ekta , Wasson, Megan , Mara, Kristin C. , Kuhle, Carol L. , Mara, Kristin, Enders, Felicity T, Faubion, Stephanie, Kuhle, Carol, Mara, Kristin C , Wasson, Megan , Kling, Juliana M. , Kapoor, Ekta , Enders, Felicity , Faubion, Stephanie S.

Mayo Clinic

The Journal of Sexual Medicine | August 12, 2022 | Volume: 19 | Issue: 10 | Pages: 1553-1561

10.1016/j.jsxm.2022.07.009 | PMID 35970712 Get It

ABSTRACT Background Studies have found that women with endometriosis have a higher risk of female sexual dysfunction (FSD). Aim To evaluate the relationship between self-reported endometriosis and FSD utilizing validated surveys. Methods A cross-sectional analysis was conducted among sexually active women aged 18–90 who presented to 3 Mayo Clinic sites from 2015 to 2021. FSD was determined utilizing a combined endpoint of Female Sexual Function Index score ≤ 26.55 and Female Sexual Distress Scale-Revised score ≥ 11. Associations between history of endometriosis and FSD were evaluated by fitting 3 multivariable logistic models and were stratified by menopause status. In the first model, the association was adjusted for age, BMI, race/ethnicity, marital status, and education. The second model adjusted for the variables in Model 1 and hormone therapy, hormonal contraceptive use, self-reported history of abuse within the last year, and co-morbidities including the history of diabetes, heart disease, hypertension, osteoporosis, and stroke. The third model adjusted for the variables in Model 1, Model 2, and anxiety, depression, relationship satisfaction, and SSRI/SNRI use. Outcomes The outcomes included self-reported endometriosis and female sexual dysfunction determined utilizing a combined endpoint of Female Sexual Function Index score ≤ 26.55 and Female Sexual Distress Scale-Revised score ≥ 11. Results Of 7118 patients (mean age 51.3), 92.2% were white, 78.4% were peri- or postmenopausal, 8.7% reported endometriosis history, and 57.2% met the criteria for FSD. Women with endometriosis were more likely to be overweight or obese, be smokers, have had a history of heart disease and osteoporosis, have had anxiety and depressed mood, have had a hysterectomy and bilateral salpingo-oophorectomy, and have used hormone therapy. Compared to those without endometriosis, women with endometriosis were significantly more likely to have FSD only among premenopausal women (74.2% vs 57.4%). Similarly, in multivariable analysis the relationship was only seen for premenopausal women in all 3 models (Model 1: OR 2.74 (95% CI 1.43–5.27); Model 2: OR 2.55 (95% CI 1.30–5.04); Model 3: OR 2.30 (95% CI 1.13–4.68)). Clinical Implications These findings highlight the opportunity for healthcare practitioners to evaluate sexual function in premenopausal women with endometriosis. For peri and postmenopausal women with endometriosis, the risk of FSD was lower than for premenopausal women with endometriosis. Strengths and Limitations This study analyzed the association between endometriosis and FSD in women by menopause status using validated tools that included a measure of distress associated with sexual dysfunction. Limitations include its cross-sectional design which does not allow for determination of the direction of this association. Conclusion The risk for FSD associated with endometriosis depends on menopause status. Endometriosis increased the odds of FSD only in premenopausal women.
Ethical Considerations in Palliative Reconstruction
Kandi, Lyndsay A. , Struve, Sara L., Teven, Chad M. , Hammond, Jacob B.

Mayo Clinic

Plastic & Reconstructive Surgery | August 12, 2022 | Volume: 150 | Issue: 4 | Pages: 938e-939e

10.1097/prs.0000000000009516 | PMID 35960920 Get It

Exposure Therapy for Child and Adolescent Anxiety and OCD
Whiteside, Stephen P. H. , Ollendick, Thomas H. , Biggs, Bridget K.

Mayo Clinic

No container title available | August 12, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/med-psych/9780190862992.001.0001 Get It

Abstract Exposure is the most important component of therapy for anxiety disorders and obsessive–compulsive disorder (OCD) in children and adolescents. Unfortunately, few clinicians offer this treatment, making it very difficult for youth and their families to seek effective care. In this installment of the Association for Behavioral and Cognitive Therapy’s Series on Implementation of Clinical Approaches, Whiteside, Ollendick, and Biggs deliver a succinct yet comprehensive guide to the use of exposure therapy with youth suffering from anxiety and OCD. Within the heart of this book, clinicians will discover a clear step-by-step model, illustrated with sample dialogue, for engaging their young patients in this most effective treatment. Detailed case examples bring to life the application of all forms of exposure (in vivo, imaginal, and interoceptive) to a wide range of anxiety and OCD presentations. Beyond teaching the mechanics for implementing exposure, the authors present a clinical model for understanding how exposure works, synthesizing the key issues from current competing theories. This model can enhance the ability of clinicians to apply exposure to new and more challenging presentations. In addition, the authors review common challenges to implementing exposure in real-world settings to assist clinicians in overcoming frequently encountered barriers. Clinicians can feel confident in the validity of the approach as the authors concisely review the foundation of history and research supporting exposure. Within this compact book, clinicians will find a comprehensive guide to build their expertise in the delivery of exposure therapy for children and adolescents suffering from anxiety disorders or OCD.
Virtual particle Monte Carlo: A new concept to avoid simulating secondary particles in proton therapy dose calculation
Shan, Jie , Feng, Hongying , Morales, Danairis Hernandez, Patel, Samir H. , Wong, William W. , Fatyga, M., Foote, Robert L. , Fatyga, Mirek, Schild, Steven E. , Bues, Martin , Liu, Wei

Mayo Clinic

Medical Physics | August 12, 2022 | Volume: 49 | Issue: 10 | Pages: 6666-6683

10.1002/mp.15913 | PMID 35960865 Get It

AbstractBackgroundIn proton therapy dose calculation, Monte Carlo (MC) simulations are superior in accuracy but more time consuming, compared to analytical calculations. Graphic processing units (GPUs) are effective in accelerating MC simulations but may suffer thread divergence and racing condition in GPU threads that degrades the computing performance due to the generation of secondary particles during nuclear reactions.PurposeA novel concept of virtual particle (VP) MC (VPMC) is proposed to avoid simulating secondary particles in GPU‐accelerated proton MC dose calculation and take full advantage of the computing power of GPU.MethodsNeutrons and gamma rays were ignored as escaping from the human body; doses of electrons, heavy ions, and nuclear fragments were locally deposited; the tracks of deuterons were converted into tracks of protons. These particles, together with primary and secondary protons, are considered to be the realistic particles. Histories of primary and secondary protons were replaced by histories of multiple VPs. Each VP corresponded to one proton (either primary or secondary). A continuous‐slowing‐down‐approximation model, an ionization model, and a large angle scattering event model corresponding to nuclear interactions were developed for VPs by generating probability distribution functions (PDFs) based on simulation results of realistic particles using MCsquare. For efficient calculations, these PDFs were stored in the Compute Unified Device Architecture textures. VPMC was benchmarked with TOPAS and MCsquare in phantoms and with MCsquare in 13 representative patient geometries. Comparisons between the VPMC calculated dose and dose measured in water during patient‐specific quality assurance (PSQA) of the selected 13 patients were also carried out. Gamma analysis was used to compare the doses derived from different methods and calculation efficiencies were also compared.ResultsIntegrated depth dose and lateral dose profiles in both homogeneous and inhomogeneous phantoms all matched well among VPMC, TOPAS, and MCsquare calculations. The 3D–3D gamma passing rates with a criterion of 2%/2 mm and a threshold of 10% was 98.49% between MCsquare and TOPAS and 98.31% between VPMC and TOPAS in homogeneous phantoms, and 99.18% between MCsquare and TOPAS and 98.49% between VPMC and TOPAS in inhomogeneous phantoms, respectively. In patient geometries, the 3D–3D gamma passing rates with 2%/2 mm/10% between dose distributions from VPMC and MCsquare were 98.56 ± 1.09% in patient geometries. The 2D–3D gamma analysis with 3%/2 mm/10% between the VPMC calculated dose distributions and the 2D measured planar dose distributions during PSQA was 98.91 ± 0.88%. VPMC calculation was highly efficient and took 2.84 ± 2.44 s to finish for the selected 13 patients running on four NVIDIA Ampere GPUs in patient geometries.ConclusionVPMC was found to achieve high accuracy and efficiency in proton therapy dose calculation.
SAMCNet: Towards a Spatially Explainable AI Approach for Classifying MxIF Oncology Data
Farhadloo, Majid , Molnar, Carl , Luo, Gaoxiang , Li, Yan , Maus, Rachel L.G., Leontovich, Alexey A. , Moore, Raymond C., Shekhar, Shashi , Markovic, Svetomir N. , Moore, Raymond

Mayo Clinic

Proceedings of the 28th ACM SIGKDD Conference on Knowledge Discovery and Data Mining | August 12, 2022 | Volume: No volume available | Issue: No issue available | Pages: 2860-2870

10.1145/3534678.3539168 Get It

A Rare Case Report of NEHI in a Preterm Infant with Review of the Literature
Mangat, Chetna , DeCoster, Mikaela, Milosavljevic, Natasa, Hiskey, Lisa , Ristagno, Elizabeth H. , Demirel, Nadir

Mayo Clinic

Case Reports in Pediatrics | August 12, 2022 | Volume: 2022 | Issue: No issue available | Pages: 1-4

10.1155/2022/7907338 | PMID 35992743 Get It

Background. Neuroendocrine cell hyperplasia of infancy (NEHI) is a rare respiratory disorder. During infancy, it typically presents with hypoxemia, tachypnea, and respiratory distress, and is commonly misdiagnosed as common childhood illnesses such as pneumonia, reactive airway disease, or bronchiolitis. Lack of awareness about this relatively new and rare disorder in primary care and acute care settings lead to delayed diagnosis and unnecessary use of antibiotics. Case Presentation. We present a case of a 7-month-old girl, born prematurely at 32 weeks with tachypnea and respiratory distress who was initially diagnosed with viral pneumonia, then upper respiratory infection, and finally with community-acquired bacterial pneumonia, while the child never had any fever or upper respiratory symptoms. Failure of outpatient treatment with oral antibiotic and bronchodilator, with the persistence of respiratory symptoms such as retractions, bilateral crackles, and hypoxemia led to hospitalization for intravenous antibiotics. Given persistent symptoms, further evaluation was performed, and she was diagnosed with NEHI based on characteristic chest CT findings. Conclusions. Viral respiratory infections are the most frequent cause of respiratory illnesses in the first years of life. Primary care providers should be aware of less frequent causes of persistent respiratory symptoms in infancy like NEHI and other interstitial lung diseases in children. This may prevent unnecessary use of antibiotics and delayed diagnosis.
Differential proteomic expression in indolent vulvar lichen sclerosus, transforming vulvar lichen sclerosus and normal vulvar tissue
Gleue, Casey A. , Xie, Fangyi , Deschaine, Maria , Dasari, Surendra , Sartori‐Valinotti, Julio C. , Torgerson, Rochelle R. , Davis, Mark D. P. , Charlesworth, M. Cristine , Meves, Alexander , Lehman, Julia S. , Lehman, Julia S , Davis, Mark D.P. , Charlesworth, M. Cristine

Mayo Clinic

Experimental Dermatology | August 12, 2022 | Volume: 31 | Issue: 12 | Pages: 1920-1926

10.1111/exd.14660 | PMID 35960231 Get It

AbstractVulvar lichen sclerosus (VLS) confers approximately 3% risk of malignant transformation to vulvar squamous cell carcinoma (VSCC). We used unbiased proteomic methods to identify differentially expressed proteins in tissue of patients with VLS who developed VSCC compared to those who did not. We used laser capture microdissection‐ and nanoLC‐tandem mass spectrometry to assess protein expression in individuals in normal vulvar tissue (NVT, n = 4), indolent VLS (no VSCC after at least 5 years follow‐up, n = 5) or transforming VSCC (preceding VSCC, n = 5). Interferon‐γ and antigen‐presenting pathways are overexpressed in indolent and transforming VLS compared to NVT. There was differential expression of malignancy‐related proteins in transforming VLS compared to indolent VLS (CAV1 overexpression, AKAP12 underexpression), particularly in the EIF2 translation pathway, which has been previously implicated in carcinogenesis. Results of this study provide additional molecular evidence supporting the concept that VLS is a risk factor for VSCC and highlights possible future biomarkers and/or therapeutic targets.
Total shoulder arthroplasty versus reverse total shoulder arthroplasty: Outcome comparison in osteoarthritis patients with or without concurrent rotator cuff deficiency
Huang, Tony Chieh‐Ting , Yu, Hanzhong, Wang, Yicun , Wang, Daping , Long, Zeling , Long, Zeling , Liu, Haifeng

Mayo Clinic

Medicine | August 12, 2022 | Volume: 101 | Issue: 32 | Pages: e29896

10.1097/md.0000000000029896 | PMID 35960077 Get It

Osteoarthritis (OA) is a common shoulder disorder that impacts shoulder functions. Shoulder arthroplasty is often required to restore function and quality of life. Reverse total shoulder arthroplasty (RSA), which was originally designed mainly for irreparable rotator cuff damage, has gained popularity in recent years for the treatment of advanced shoulder OA instead of the clinically standard total shoulder arthroplasty (TSA). However, this RSA has some nonnegligible flaws such as higher complications rate and economic cost, not mention the following problems caused by irreversible physical structural damage. Therefore, the employment of RSA needs to be carefully considered. This study aimed to compare TSA and RSA in OA patients with or without rotator cuff damage to better guide clinical decision making. We believe the radical use of RSA in patients without rotator cuff deficiency may cause more harm than good. We queried the Nationwide Inpatient Sample (NIS) database from 2011 to 2014 to collect information on OA patients who received TSA and RSA. Patients were divided into 2 groups of comparison according to the presence of rotator cuff deficiency and matched with propensity score analysis. A total of 57,156 shoulder arthroplasties were identified. RSA patients in the rotator cuff deficiency group had significant higher transfusion rates and longer hospital stays. RSA patients without rotator cuff deficiency had a statistically significantly higher number of implant-related mechanical complications, acute upper respiratory infections and postoperative pain. Overall, RSA incurred higher costs in both groups. For OA patients with rotator cuff deficiencies, RSA has its benefits as complication rates were comparable to TSA. For those patients without rotator cuff deficiencies, the use of RSA should be reconsidered as there were more complications with higher severity.
Medical Marijuana Use for Cancer-Related Symptoms among Floridians: A Descriptive Study
Tofthagen, Cindy , Advani, Pooja , Kaur, Judith S. , Tan, Winston , Sheffield, Katharine, Henry, Joshua, Starr, Jason S. , Perlman, Adam , Kaur, Judith, Tofthagen, Cindy S , Ernst, Brenda , Crump, John A. , Henry, Joshua

Mayo Clinic

Journal of Palliative Medicine | August 12, 2022 | Volume: 25 | Issue: 10 | Pages: 1563-1570

10.1089/jpm.2022.0100 | PMID 35960820 Get It

Background: Thirty-six states, including Florida, have legalized marijuana for medical and/or recreational use, yet how it is used and perceived by persons with cancer is not well understood. Objectives: The purpose of this study was to identify patterns of use, perceived benefits, and side effects of medical marijuana (MMJ) among cancer patients in Florida. Methods: For this descriptive, cross-sectional study, anyone residing within the state of Florida who was diagnosed or treated for a malignancy within the last five years and had used MMJ was eligible. An online survey containing questions about dosing, side effects, perceived benefits, and barriers to use was used. Descriptive statistics including frequencies, percentages, means, and standard deviations were used to analyze quantitative data. Responses to open-ended questions were coded and categorized. Results: Sleep ( n = 112), pain ( n = 96), and anxiety ( n = 82) were the most common symptoms participants used MMJ to relieve and overall felt it was highly effective. MMJ was well tolerated with a minority (10.3%) reporting any adverse effects. Cost was the most frequent barrier reported by participants (42.8%). A variety of legal, bureaucratic, and system-related barriers were described. Conclusion: Participants perceived MMJ to be helpful in alleviating cancer symptoms. They held negative perceptions of the way MMJ is implemented and integrated into their oncology treatment plan. Enhanced communication and patient/provider education on MMJ are needed to inform patient decision making.